Skip to content
To the full analysis

Intco Medical Technology stock: Analyst Forecast

300677.SZ
$7.23Closing price of 20 Nov 2026MEQIRI Score 45 out of 100

For Intco Medical Technology, analysts expect revenue of $2.16B (up 45.2%) and adjusted earnings per share of $0.40 (up 1.5%) on average for fiscal year 2026. For 2027 they expect revenue of $2.4B (up 11.2%) and adjusted earnings per share of $0.62 (up 52.7%). That is the average of the estimates of 3 analysts.

Daily figure as of 20 Nov 2026

Revenue 2026 expected
$2.16B
+45.2% on the prior year
Revenue 2027 expected
$2.4B
+11.2% on the prior year
EPS 2026 expected
$0.40
+1.5% on the prior year
EPS 2027 expected
$0.62
+52.7% on the prior year

Reported and Expected

Fiscal yearTypeRevenueGrowthNet incomeNet marginEPSAnalysts
2023Reported$1.04B4.6%$57.45M5.5%$0.09
2024Reported$1.43B37.6%$219.82M15.4%$0.34
2025Reported$1.49B4.2%$151.6M10.2%$0.24
2026Estimate$2.16B45.2%$229.43M10.6%$0.403
2027Estimate$2.4B11.2%$383.45M16.0%$0.623

Earnings per share in the estimates are usually adjusted, the way analysts calculate them. The reported figure is the statutory one and can therefore differ.

What the Estimates Show

The expected revenue growth for 2026 of +45.2% is above the average of fiscal years 2020 to 2025 of −6.4% per year. Earnings per share are expected to grow more slowly than revenue in 2026, by 1.5% against 45.2%. The expected net margin rises from 10.6% in 2026 to 16% in 2027.

In all 4 quarters with comparable figures, Intco Medical Technology met the analysts' expectation for revenue within 2%. In the report of 28 Oct 2026, revenue came in line with the expectation (−1.0%).

A reported figure within 2% of the expectation counts as in line.

How Intco Medical Technology Compares

Among the 38 other stocks in the Medical (Instruments & Supplies) industry with a forward P/E, the median is 22. At 12.9, Intco Medical Technology is below it.

Estimates of Industry Peers

Among industry peers, analysts expect the strongest revenue growth at Gan & Lee Pharmaceuticals. (+16%) and the weakest at Stevanato Group (+2.3%).

StockExpected revenue growthForward P/E
Teleflex+3.8%15.5
Gan & Lee Pharmaceuticals.+16%no data
Merit Medical Systems+6.1%18.2
ICU Medical+4.1%18.4
Stevanato Group+2.3%22.9

Revenue growth here means the next fiscal year against the current one, both analyst averages.

Forecast and Fair Value

The forward P/E of Intco Medical Technology is 12.9, below the P/E on statutory earnings of the last twelve months (108.9). It uses the earnings analysts expect for the next twelve months. MEQIRI's fair value for Intco Medical Technology is $8.00, 4.7% above the share price. Its cash flow part uses the analysts' estimates for the first 3 years.

Why There Is No Price Target Here

MEQIRI deliberately does not show price targets or buy and sell recommendations, because they are opinions about the future share price. Revenue and earnings, by contrast, can be checked against every report.

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.